X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 2018 (-) 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2017 December 17, 2017 argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million December 13, 2017 argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering December 12, 2017 argenx announces size of proposed public offering in the United States updated to 3.5 million ADSs December 10, 2017 argenx announces launch of proposed public offering in the United States December 10, 2017 argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis December 10, 2017 argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting November 12, 2017 argenx to Present at Upcoming Investor Conferences November 6, 2017 argenx announces results of extraordinary shareholders’ meeting 2017 November 1, 2017 argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017 October 29, 2017 argenx launches Phase I trial with subcutaneous formulation of ARGX-113 October 25, 2017 argenx reports third quarter 2017 financial results and September 25, 2017 argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next › Last page Last »